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ShK, a 35-residue peptide from a sea anemone, is a potent blocker of potassium channels. Here we
describe a new ShK analogue with an additional C-terminus Lys residue and amide. ShK-K-amide is
a potent blocker of Kv1.3 and, in contrast to ShK and ShK-amide, is selective for Kv1.3. To under-
stand this selectivity, we created complexes of ShK-K-amide with Kv1.3 and Kv1.1 using docking
and molecular dynamics simulations, then performed umbrella sampling simulations to construct
the potential of mean force of the ligand and calculate the corresponding binding free energy for
the most stable conﬁguration. The results agree well with experimental data.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Lys22 of ShK projecting into and occluding the ion conductionThe voltage-gated potassium channel Kv1.3 is signiﬁcantly up-
regulated in activated effector memory (TEM) cells in humans
[1,2]. As a consequence, Kv1.3 blockers constitute valuable new
therapeutic leads for the treatment of autoimmune diseases med-
iated by TEM cells, such as multiple sclerosis and rheumatoid
arthritis [1–4].
ShK toxin, a 35-residue peptide from the sea anemone
Stichodactyla helianthus [5,6], is a potent blocker of potassium
channels. Its solution structure (Fig. 1) has been determined [7,8]
and the surface involved in binding to Kv channels has been
mapped using alanine scanning and synthetic analogues [9–11].
The essential residues are clustered on a surface of the peptide that
binds to a shallow vestibule at the outer entrance to the ion
conduction pathway and blocks the entrance to the pore, withchemical Societies. Published by E
ltage-gated K+ channel; ShK,
mide, C-terminally amidated
de; MD, molecular dynamics;
on).pathway [12–14].
ShK blocks not only Kv1.3 (Kd 11 pM) but also Kv1.1 (Kd 16 pM),
Kv1.7 [12] and Kv3.2 channels [15,16]. As this lack of speciﬁcity
constitutes a potential drawback for the use of ShK as a therapeutic
agent [4], a considerable effort has been devoted to developing
ShK analogues that are selective for Kv1.3 over Kv1.1 and other
potassium channels. More selective analogues have been created
by the incorporation of non-natural amino acids or adducts,
including ShK-Dap22, in which Lys22 was replaced by the posi-
tively-charged, non-natural residue 1,3-diaminopropionic acid
(Dap) [12], ShK-F6CA, a ﬂuorescein-labelled analogue of ShK [17],
and analogues with either phospho-Tyr (ShK-186) or phosphono-
Phe (ShK-192) attached via a hydrophilic linker to Arg1 [15,18].
However, these analogues have several potential limitations, for
example, ShK-186 and ShK-192 contain non-protein adducts and
the phosphorylated residue of ShK-186 is susceptible to hydrolysis.
As a result, there is still scope for the development of new
analogues with enhanced stability and increased speciﬁcity for
Kv1.3.
In this study we describe a new analogue of ShK modiﬁed
at the C-terminus (Fig. 1) by addition of a Lys residue and amide.lsevier B.V. All rights reserved.
Fig. 1. Structure of ShK (PDB id 1ROO). The backbone and three disulﬁde bridges
(Cys3-Cys35, Cys12-Cys28 and Cys17-Cys32) are shown for the closest-to-average
solution structure [7].
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in contrast to ShK and ShK-amide, both of which lack selectivity for
Kv1.3. In an effort to understand the molecular basis for this
selectivity, we have created complexes of this peptide with Kv1.3
and Kv1.1 channels using docking and molecular dynamics (MD)
simulations. Umbrella sampling simulations were then performed
to construct the potential of mean force (PMF) of the ligand andFig. 2. RP-HPLC chromatograms for the (A) folding of crude ShK-Kamide (after 18 h) and
30 min at a ﬂow rate of 1 ml/min. Absorbance monitored at 220 nm. The peak eluting acalculate the corresponding binding free energy for the most stable
conﬁguration [19].
2. Materials and methods
2.1. Peptide synthesis
ShK-K-amide was synthesized on a Prelude peptide synthesizer
using an Fmoc-tBu strategy. The peptide was synthesized starting
with Rink amide resin (Peptides International, Louisville, KY). All
couplings were mediated with diisopropyl carbodiimide and 6-
chloro-hydroxybenzotriazole. Following solid-phase assembly of
the linear peptide chain, the peptide was cleaved from the solid
support and simultaneously deprotected using Reagent K for 2 h
at room temperature. The crude peptide was precipitated into ice
cold diethyl ether and washed thoroughly to remove cationic scav-
engers from the cleavage cocktail, dissolved in 50% aqueous acetic
acid, then diluted in water and the pH adjusted to 8.0 with NH4OH.
Disulﬁde bond formation was facilitated with reduced and
oxidized glutathione according to previously used protocols for
ShK [9].
The progress of folding was followed by RP-HPLC using a Phe-
nomenex Luna C18 column using a gradient of acetonitrile versus
H2O containing 0.05% TFA from 10–70% over 35 min. Folding of
the three disulﬁde bonds was also conﬁrmed by the loss of 6 mass
units from the crude material as determined by ESI-MS.
2.2. Modelling and docking
Here we give a brief description of the computational methods
and refer to the Supplementary data and [19,20] for details. The
structure of ShK-K-amide was generated from that of ShK [7] using
the mutator plugin in the VMD software [21]. For the Kv1.1 and
Kv1.3 structures, we used the homology models developed in
[19]. The initial poses for the Kv1.x–ShK-K-amide complexes were
found using the docking program HADDOCK [22], and then reﬁned(B) ﬁnal puriﬁed ShK-Kamide. The gradient conditions are 10–50% acetonitrile over
t 12 min is the correctly folded ShK-K amide.
Fig. 3. (A) ShK (top), ShK-amide (middle) and ShK-K-amide (bottom) on Kv1.3 (left)
and Kv1.1 (right) currents in stable transfected L929 cells. (B) Dose-dependent
inhibition of Kv1.3 (left) and Kv1.1 (right) by ShK (s, n = 4 cells each), ShK-amide
(h, n = 3 cells each), and ShK-K-amide (j, n = 3 cells each). (C) Dose-dependent
inhibition of the proliferation of human T lymphocytes by ShK (s), ShK-186 (d),
and ShK-K-amide (j).
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ther run for 20 ns to check equilibration and for data analysis. MD
simulations were performed using the NAMD program [23] with
the CHARMM22 force ﬁeld [24] including the CMAP correction
[25]. The PMF of each toxin was determined from the umbrella
sampling MD simulations using the weighted histogram analysis
method [19,26].
2.3. Cells and cell lines
L929 mouse ﬁbroblast cells stably expressing mKv1.1 and
mKv1.3 channels [27] were gifts from Dr. K. George Chandy
(University of California, Irvine). They were maintained in DMEM
medium (Invitrogen, Carlsbad, CA) supplemented with 100 IU/ml
penicillin, 0.1 lg/ml streptomycin, 2 mM L-glutamine, 10% heat-
inactivated fetal bovine serum, and 0.5 mg/ml G418 (EMD Chemi-
cals, Gibbstown, NJ).
Freshly prepared buffy coats were purchased from the Gulf
Coast Regional Blood Center (Houston, TX) under a protocol ap-
proved by the Baylor College of Medicine Institutional Review
Board. Mononuclear cells were isolated from the buffy coats usingHistopaque-1077 gradients (Sigma, St Louis, MI) and used
immediately.
2.4. Electrophysiological analysis
Experiments were conducted at room temperature in the
whole-cell conﬁguration of the patch-clamp technique. A manual
setup and an automated Port-a-patch setup (Nanion, North Bruns-
wick, NJ) were used in parallel, both linked to a HEKA EPC10USB
ampliﬁer. The patch pipettes or chips had a resistance of 2–4 MX
when ﬁlled with an internal solution containing (in mM): 145 KF,
10 HEPES, 10 EGTA, and 2 MgCl2, pH 7.2, 290 mOsm. The bath solu-
tion contained (in mM): 160 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 10
HEPES, pH 7.2, 300 mOsm. Kv currents were elicited every 30 s
by 200-ms depolarizing pulses from a holding potential of
80 mV to 40 mV. Kd values and Hill coefﬁcients were determined
by ﬁtting the Hill equation to the reduction of peak current mea-
sured at 40 mV.
2.5. T lymphocyte proliferation assays
Proliferation assays were conducted as described previously
[15]. Brieﬂy, mononuclear cells (105/well) were plated into 96-well
plates and pre-incubated with the peptide blockers for 30 min at
37 C in RPMI medium (Invitrogen) supplemented with 100 IU/ml
penicillin, 0.1 lg/ml streptomycin, 2 mM L-glutamine, 1 mM so-
dium pyruvate, 1% non-essential amino acids, 1% RPMI vitamins,
50 lM b-mercaptoethanol, and 1% heat-inactivated fetal bovine
serum. T lymphocyte activation and proliferation was induced by
the addition of 40 ng/ml anti-CD3 antibodies (Clone OKT3, eBio-
science, San Diego, CA). Cells were cultured for 72 h at 37 C, 5%
CO2, and [3H] thymidine was added during the last 16–18 h of cul-
ture. Cells were lysed by freezing at 20 C. After thawing, DNA
was harvested onto ﬁbreglass ﬁlters using a cell harvester (Inotech
Biosystems International, Rockville, MD). [3H] thymidine incorpo-
ration into the DNA of proliferating cells was measured using a
b-scintillation counter (Beckman Coulter, Brea, CA).3. Results
3.1. Peptide synthesis
The desire to modify ShK at a site distant from its key pharma-
cophore led us to consider the C-terminus (Fig. 1). We therefore
added a C-terminal Lys amide to the native sequence as this Lys
would be located outside the Cys3-Cys35 disulﬁde loop and should
not interfere with peptide folding. Amidation was included to en-
hance resistance to exoproteases. The peptide was assembled
using standard Fmoc-tBu solid-phase peptide synthesis. The crude
product was oxidized using the glutathione-mediated oxidative
folding conditions that have been used successfully for many other
ShK analogues [9]. As shown in Fig. 2A, the peptide folded rapidly,
resulting in the typical pattern of a major earlier-eluting peak by
RP-HPLC followed by later-eluting misfolded and side-product spe-
cies. ShK-K-amide was puriﬁed to homogeneity by preparative RP-
HPLC, as shown in Fig. 2B. The peptide had the correct mass by ESI-
MS (data not shown), demonstrating that the three disulﬁde bonds
had been formed. The yield was 16% of theory based upon the
starting resin.
3.2. Potency and selectivity of potassium channel blockade
We used patch-clamp electrophysiology to determine the po-
tency and selectivity of ShK and ShK-K-amide on Kv1.3 and
Kv1.1 channels (Fig. 3A, B). As described previously [12,28], ShK
Fig. 4. Snapshots of ShK-K-amide (yellow with coloured side chains) in complex with Kv1.1 (A) and Kv1.3 (B) channels, showing the important residues involved in the
binding. To indicate the changes in the binding modes, ShK (transparent yellow), in complex with the same channels, is superimposed on the ﬁgures after aligning the Kv1
channels. Only the A and C monomers of Kv1.1 and Kv1.3 are shown to avoid cluttering. Relative to the view of Kv1.1 in part A, and with the standard deﬁnition of the axes,
Kv1.3 (B) is rotated around z by ca 5 clockwise and around y by ca 5 clockwise. This makes channel subunit A look slightly larger than C.
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9 ± 2 pM for Kv1.3 and 23 ± 3 pM for Kv1.1). ShK-K amide retained
a high afﬁnity for the Kv1.3 channels (IC50 26 ± 3 pM) but displayed
a much lower afﬁnity for Kv1.1 channels (IC50 942 ± 120 pM)
resulting in a 36-fold selectivity for Kv1.3 over Kv1.1 channels.
As a control for the contribution of the C-terminal amidation of
ShK in this increase in selectivity of ShK-K-amide, we determined
the potency of ShK-amide on both channels and found that the
C-terminal amidation did not affect the selectivity of the peptide,
with IC50 values of 35 ± 5 pM on Kv1.3 and 37 ± 4 pM on Kv1.1
channels.
3.3. Inhibitory effects on human T lymphocyte proliferation
Kv1.3 channel blockers are potent inhibitors of the proliferation
of human T lymphocytes. ShK-K-amide inhibited the proliferation
of freshly-isolated human T cells with a similar potency(IC50  3 nM) to that of ShK and its well-characterized analogue
ShK-186 (Fig. 3C) [1,2,28,29].
3.4. Interactions of ShK-K-amide with Kv1.3 and Kv1.1
Addition of an amidated Lys to the C-terminus of ShK changes
the total charge at the C-terminus from negative to positive. This
has a major effect on the N-terminus and the Arg1 side chain in
ShK-K-amide as they are pushed away from the C-terminus and
become free to engage with channel residues (Fig. 4). In ShK, the
N-terminus and Arg1 side chain are attracted to the C-terminus,
which neutralizes their charges to a degree and prevents their
association with channel residues. Inspection of the contact dis-
tances for the Kv1.3–ShK and Kv1.3–ShK-K-amide complexes (Ta-
ble 1) and their evolution as ShK-K-amide is pulled out (Fig. S1)
shows that Arg1 becomes the dominant residue in binding of this
analogue. Contrasting the binding modes of ShK and ShK-K-amide
Table 1
Comparison of the strongly interacting residues in ShK and ShK-K-amide complexes with Kv1.1 and Kv1.3. The average atom–atom distances obtained from the MD simulations
are listed in columns 3 and 6 (in units of Å). Subscripts refer to the side chain atoms and the monomer identity is indicated in parenthesis.
ShK Kv1.1 MD average ShK-K-amide Kv1.1 MD average
R1-N2 D377-O2(D) 10.5 ± 0.5 R1-N2 D377-O1(A) 2.7 ± 0.3
R11-N2 D361-O2(B) 5.5 ± 0.5 R11-N2 E351-O1(B) 4.0 ± 0.5
K18-N1 E353-O2(C) 2.7 ± 0.2 K18-N1 E353-O2(D) 15 ± 0.5
S20-OH Y379-OH(B) 3.0 ± 0.3 S26-OH G376-O(A) 3.0 ± 0.2
K22-N1 Y375-O(ABC) 2.7 ± 0.2 K22-N1 Y375-O(BCD) 2.7 ± 0.5
F27-Ce2 Y379e1(A) 3.6 ± 0.2 F27-Cf Y379-Ce2(B) 3.7 ± 0.5
R29-N2 E353-O2(D) 2.5 ± 0.3 R29-N2 D377-O1(A) 7.3 ± 0.3
ShK Kv1.3 MD average ShK-K-amide Kv1.3 MD average
R1-N1 D376-O1(C) 4.5 ± 0.4 R1-N2 D375-O2(C) 2.7 ± 0.2
S10-OH S378-OH(C) 10.5 ± 0.2 S10-OH S378-OH(B) 3.0 ± 0.3
R11-N2 D402-O1(A) 3.5 ± 0.3 R11-N2 E373-O1(D) 4.3 ± 0.5
S20-OH G401-O(B) 2.7 ± 0.2 S26-OH G401-O(C) 2.7 ± 0.3
K22-N1 Y400-O(ABD) 2.7 ± 0.2 K22-N1 Y400-O(BCD) 2.7 ± 0.5
F27-Ce1 H404-Cc(C) 3.6 ± 0.2 F27- Ce1 H404-C!1(C) 3.6 ± 0.5
H19-NH S378-O(B) 3.0 ± 0.5 R29-N1 S379-O(C) 2.9 ± 0.5
Fig. 5. Comparison of the PMFs for the unbinding of ShK and ShK-K-amide from Kv1.1 and Kv1.3 channels.
Table 2
Binding free energies of ShK and ShK-K-amide calculated from the PMFs are
compared to the experimental values (in units of kcal/mol).
Complex DGb(PMF) DGb(exp)
Kv1.1–ShK 14.3 ± 1.1 14.5 ± 0.1
Kv1.1–ShK-K-amide 11.8 ± 1.0 12.3 ± 0.1
Kv1.3–ShK 14.2 ± 1.2 15.0 ± 0.1
Kv1.3–ShK-K-amide 14.0 ± 0.3 14.4 ± 0.1
4000 M.W. Pennington et al. / FEBS Letters 586 (2012) 3996–4001(Table 1), it is seen that Arg1 is already involved in binding of ShK
to Kv1.3 so the mutation leads to some rearrangement among the
contact pairs but their number and quality as measured by the
contact distances are preserved. In contrast, Arg1 is not involved
in binding of ShK to Kv1.1 so the C-terminal extension causes a ma-
jor disruption in the binding mode. In particular, Lys18 points
away from the channel and Arg29 is no longer coupled to any neg-
atively charged residues (Table 1; Fig. 4). The loss of these two
charge contacts, which play an important role in binding of ShK,
is not compensated by addition of Arg1 to the contact list (Table 1;
Fig. 4). From the evolution of the contact distances (Fig. S1), one
can also identify another strongly coupled pair (Arg29-Ser379) in
Kv1.3–ShK-K-amide that has no counterpart in Kv1.1–ShK-K-
amide and thus contributes to the higher afﬁnity of this analogue
for Kv1.3.
These observations imply that the binding afﬁnity of ShK-K-
amide for Kv1.1 should decrease relative to ShK while no suchchange is expected for Kv1.3. To conﬁrm these expectations, we
have computed the PMFs for dissociation of ShK-K-amide from
the Kv1.1 and Kv1.3 channels. Details of the umbrella sampling
MD simulations and convergence studies of the PMFs are provided
in the Supplementary data (Fig. S2). Comparison of the ShK-K-
amide PMFs with those of ShK (Fig. 5) shows that indeed the
afﬁnity of ShK-K-amide for Kv1.1 is reduced substantially com-
pared to that of ShK, while they are essentially the same for
Kv1.3. The standard binding free energies obtained from the PMF’s
are compared to the experimental values in Table. 2. All the calcu-
lated binding free energies agree with the experimental values
within 1 kcal/mol which is the chemical accuracy of the calcula-
tions. In particular, the C-terminal extension is predicted to cause
a 2.5 kcal/mol increase in the binding free energy of the toxin for
Kv1.1, which is in good agreement with the experimental value
of 2.2 kcal/mol.
4. Discussion
ShK-K-amide blocks Kv1.3 with an IC50 of 26 ± 3 pM, similar to
the afﬁnities for this channel of ShK (9 ± 2 pM) [12,28] and
ShK-amide (35 ± 5 pM). However, with an IC50 of 942 ± 120 pM
for Kv1.1, ShK-K-amide is far more selective for Kv1.3 over Kv1.1
than ShK, which blocks Kv1.1 with an IC50 of 23 ± 3 pM [12,28],
or ShK-amide (37 ± 4 pM). This is the ﬁrst report of an ShK
analogue with enhanced Kv1.3 selectivity following modiﬁcation
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selectivity had focused on either the pore-blocking Lys22 or the
N-terminus of ShK [3,4]. As selectivity for Kv1.3 over Kv1.1 is an
important criterion for potential therapeutic applications in the
treatment of autoimmune disease in humans [3,4], our results
suggest that analogues with this C-terminal extension may be
useful platforms for further modiﬁcation.
Our results also provide an excellent example of the applica-
tion of MD simulations and umbrella sampling PMF calculations
[19] to rationalize the effects of changes in ShK on its binding
afﬁnity for various potassium channels. ShK has almost the same
afﬁnity for Kv1.1 as for Kv1.3 but its binding modes for the two
channels are distinct. This provides a strategy for designing ShK
analogues that are selective for Kv1.3 in which ShK is modiﬁed
so as to perturb the binding mode for Kv1.1 but not Kv1.3. As
shown here, ShK-K-amide provides a nice example of this strat-
egy. In general, any C-terminal extension that results in release
of the N-terminal should yield a similar selectivity for Kv1.3 over
Kv1.1.
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